Ahead of World AIDS Day on December 1st, we asked several BC-CfE researchers about their work and how it relates to this year’s World AIDS Day theme of ‘End Inequalities. End AIDS. End Pandemics’.
Ahead of World AIDS Day on December 1st, we asked several BC-CfE researchers about their work and how it relates to this year’s World AIDS Day theme of ‘End Inequalities. End AIDS. End Pandemics’.
Ahead of World AIDS Day on December 1st, we asked several BC-CfE researchers about their work and how it relates to this year’s World AIDS Day theme of ‘End Inequalities. End AIDS. End Pandemics’. Dr. Kate Salters, a BC-CfE research scientist, leads the Viral Hepatitis Research Program.
Dr. Peter Cheung, a staff scientist in the BC-CfE laboratory, recently published a paper as a co-first author on the topic of a novel antiviral compound discovery.Dr. Cheung worked with researchers at the University of BC and the University of Toronto to characterize chemical compounds that inhibit HIV in novel ways compared to antiretroviral agents currently used. Specifically, the molecules discussed in the paper “2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing” impact the processing and production of mRNA “messages” that instruct a cell to make proteins.
Understanding the dynamics within HIV transmission clusters is critical information that can help prioritize public health resource allocation. Although HIV sequence clustering is routinely used to identify subpopulations experiencing elevated transmission, there’s a risk of over-simplifying transmission dynamics within clusters as well as the risk that clustering methodology influences outcomes.
The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS) prioritizes community-based research with a heavy focus on increasing the meaningful involvement of people living with HIV/AIDS in research, particularly women.
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
